Vitrolife AB (publ) (VITR) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Vitrolife Q2 2026 earnings call. For the first part of the presentation, participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Please start by asking one question followed by a follow-up question. It's then fine to queue up again for more questions. Now I will hand the conference over to CEO Bronwyn Brophy and CFO Par Eerskog. Please go ahead. Good morning, everyone, and thank you for dialing in to the Q2 2026 earnings call for the Vitrolife Group. I would like to start with three key highlights in the quarter. We delivered record revenue of 358 million sec in consumables, which represents 15% organic growth in our America's region. A net income of 129 million SEC and an EPS of 0.95 SEC. We also launched EmbryoCath and EmbryoViewer Pro. So for the first time, we can compete in the embryo transfer segment. EmbryoViewer Pro, which we recently showcased at the ESHRA Congress, is an advanced software program for our embryoscope time-lapse system. I will now move us on, and I would like to provide you with an overview of the market in each of our regions, starting with EMEA. European IVF cycle activities appear to be at normal levels. However, in the EMEA region, the Middle East crisis is impacting IVF cycles significantly. We do not, in the Vitrolife Group, see Middle East distributors restocking at this time. In fact, the airspace has been regularly closed, so even shipping goods into the region is a challenge. In the APAC region, which I recently visited myself, in China we see that IVF cycles are declining year over year. This trend is expected to continue based on population demographics. The Southeast Asia within APAC is growing as access...